| Objective:To explore the relations between the expression of Cyclin E protein and neoadjuvant chemotherapy in locally advanced breast cancer(LABC) patients through the detection of Cyclin E protein in patients with LABC before and after the chemotherapy. Seeking and predicting the curative effect of neoadjuvant chemotherapy for LABC related sensitive molecular proteins to provide the basis for guiding individualized treatment of breast cancer and Screening for drug resistant index to provide clinical guidance for LABC patients with neoadjuvant chemotherapy.Methods:This study recruited 68 patients of stage â…¡-â…¢with LABC recruited from June 2009 to October 2014 at the First Affiliated Hospital of Nanchang University. The preoperative core needle biopsy pathology was confirmed to be theâ…¡ infiltrating ductal carcinoma. Before the operation, these patients had received 3-6 courses of neoadjuvant chemotherapy regimens based on anthracycline plus taxane to collect core needle pathological specimens before chemotherapy and carcinoma tissue pathological specimens after the surgery, another 25 normal breast tissues which distance to lesion above 5cm were confirmed by pathology. The expression of Cyclin E in breast cancer tissue and normal mammary gland organization was detected by the En Vision immunohistochemical method, which combined with the molecular classification of specimen and histopathological MP grade to study and analyze the connection between the expression of Cyclin E and the neoadjuvant chemotherapy.Results:1.Compared with the 33.3%(10/30)positive expression rate of Cyclin E in normal mammary gland organization, that in breast cancer tissue was 57.3%(39/68). It was significantly higher in the breast cancer tissue than in normal mammary gland organization, P<0.05, there was no statistically significant difference.2.The positive expression rate of Cyclin E in the breast cancer tissue got by core needle biopsy before the neoadjuvant chemotherapy, while that in the removed breast cancer tissue after the neoadjuvant chemotherapy, P>0.05, there was no statistically significant difference. 3.In neoadjuvant chemotherapy, the positive expression of Cyclin E rate in effective disease control group(c CR+c PR) was 46.6%(21/45), while that was 78.2%(18/23) in the ineffective group(SD+PD). The positive expression rate of Cyclin E protein in the control group was obviously lower than in the ineffective group, P< 0.05, there was statistically significant difference. Before the chemotherapy, the Cyclin E positive effective rate was 53.8%(21/39) while Cyclin E negative effective rate was 82.7%(24/29). The effective rate of the Cyclin E negative group was obviously higher than that of positive group, P<0.05, there was statistically significant difference. 4. The positive expression of Cyclin E in the group of the major pathologic classified response(M&P â…£~â…¤grade) was 44.1%(19/43); In the group of the non major pathologic classified response group(M&P â… ~â…¢ grade), that was 80%(20/25); The expression of Cyclin E protein was associated with histopathology after neoadjuvant chemotherapy(M&P hierarchical), and the expression level of Cyclin E in the group of the major pathologic classified response(M&P â…£~â…¤grade) was lower than that in of the non major pathologic classified response group(M&Pâ… ~â…¢grade), P < 0.05, there was statistically significant difference. 5.The expression of Cyclin E was statistically associated with age, menopausal status, clinical stage, pathological classification and lymph node metastasis, P>0.05.Conclusions:1.Compared with normal mammary gland tissue, the expression of Cyclin E in the cancerous tissue of the LABC patients was significantly increased, which showed high expression of Cyclin E might be related to occurrence and progress of breast cancer. 2. Anthracene ring yew chemotherapy drugs of Cyclin E gene transcribed and translated into protein process without inhibition. 3. The expression of Cyclin E might the clinical efficacy of neoadjuvantchemotherapy. Clinically, curative effect could be evaluated through the detection of and comparation with the expression of Cyclin E in LABC patients before and after Neoadjuvant chemotherapy to provide clinical guidance for the neoadjuvant chemotherapy of breast cancer in the future. 4. The expression of Cyclin E with patients age, menopausal status, clinical stage, pathological classification, lymph node metastasis was the conditions had not statistical correlation. |
PDF Full Text Request